UBS Group’s Cullinan Oncology CGEM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.34M | Buy |
311,309
+32,490
| +12% | +$245K | ﹤0.01% | 3692 |
|
|
2025
Q1 | $2.11M | Buy |
278,819
+43,106
| +18% | +$326K | ﹤0.01% | 3659 |
|
|
2024
Q4 | $2.87M | Buy |
235,713
+50,160
| +27% | +$611K | ﹤0.01% | 3427 |
|
|
2024
Q3 | $3.11M | Buy |
185,553
+25,573
| +16% | +$428K | ﹤0.01% | 2664 |
|
|
2024
Q2 | $2.79M | Sell |
159,980
-6,760
| -4% | -$118K | ﹤0.01% | 2562 |
|
|
2024
Q1 | $2.84M | Buy |
166,740
+25,961
| +18% | +$442K | ﹤0.01% | 2689 |
|
|
2023
Q4 | $1.43M | Buy |
140,779
+37,316
| +36% | +$380K | ﹤0.01% | 3146 |
|
|
2023
Q3 | $936K | Buy |
103,463
+12,396
| +14% | +$112K | ﹤0.01% | 3131 |
|
|
2023
Q2 | $980K | Sell |
91,067
-9,985
| -10% | -$107K | ﹤0.01% | 3325 |
|
|
2023
Q1 | $1.03M | Buy |
101,052
+2,899
| +3% | +$29.7K | ﹤0.01% | 3150 |
|
|
2022
Q4 | $1.04M | Buy |
98,153
+7,086
| +8% | +$74.8K | ﹤0.01% | 3110 |
|
|
2022
Q3 | $1.17M | Sell |
91,067
-709
| -0.8% | -$9.09K | ﹤0.01% | 2746 |
|
|
2022
Q2 | $1.18M | Sell |
91,776
-33,133
| -27% | -$425K | ﹤0.01% | 2774 |
|
|
2022
Q1 | $1.31M | Buy |
124,909
+103,167
| +475% | +$1.08M | ﹤0.01% | 3007 |
|
|
2021
Q4 | $336K | Buy |
21,742
+17,749
| +445% | +$274K | ﹤0.01% | 4268 |
|
|
2021
Q3 | $90K | Buy |
3,993
+2,027
| +103% | +$45.7K | ﹤0.01% | 4822 |
|
|
2021
Q2 | $50K | Sell |
1,966
-1,127
| -36% | -$28.7K | ﹤0.01% | 5364 |
|
|
2021
Q1 | $129K | Buy |
+3,093
| New | +$129K | ﹤0.01% | 4781 |
|